Document Detail


The Role of Lipoprotein-Associated Phospholipase A(2) as a Marker and Potential Therapeutic Target in Atherosclerosis.
MedLine Citation:
PMID:  21207201     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme that generates inflammatory mediators within atherosclerotic plaques. In epidemiologic studies there is an association between higher plasma Lp-PLA(2) activity and myocardial infarction, stroke and cardiovascular mortality. In animal models, darapladib, a specific inhibitor of Lp-PLA(2,) decreases the size of the atheroma necrotic core and plaques with thin fibrous caps. Early clinical trials suggest darapladib effectively and safely inhibits Lp-PLA(2) activity both in plasma and in carotid atheroma. Two large phase III clinical trials that are currently in progress will determine whether darapladib will reduce the risk of myocardial infarction, stroke, and cardiovascular death by stabilizing atherosclerotic plaques.
Authors:
Ralph A H Stewart; Harvey D White
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-5
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  -     ISSN:  1534-6242     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Auckland, 1030, New Zealand, RStewart@adhb.govt.nz.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hormonal Manipulation Strategies in the Management of Menstrual Migraine and Other Hormonally Relate...
Next Document:  The Role of Beta-Blockers as First-Line Therapy in Hypertension.